Last $68.18 USD
Change Today +0.39 / 0.58%
Volume 1.1M
As of 6:40 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by ASTRAZENECA PLC-SPONS ADR (AZN) in the last 6 months

Announced 03/2/15
Corridor Pharmaceuticals, Inc.
Merger/Acquisition

AstraZeneca PLC (LSE:AZN) acquired Corridor Pharmaceuticals, Inc. from Acidophil, LLC, MedImmune Ventures, Inc. and other investors in 2014.


AZN's price was unchanged after the transaction was announced on 03/2/15.
Investor / Buyer
AstraZeneca PLC
Creditor / Lender
Acidophil, LLC
Domain Associates, L.L.C.
Domain Partners VI, L.P.
MedImmune Ventures, Inc.
NewSpring Capital
Osage Partners LLC
 
Announced 12/19/14
502.00M for Moderna Therapeutics, Inc.
Private Placement

Moderna LLC announced that it will receive $502,168,634 in funding on December 19, 2014. The company will issue series E preferred units in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. As of January 5, 2015, the company received $446,069,409 from 43 investors including new investors Viking Global Investors LP, Invus, RA Capital Management, and Wellington Management Company, LLP. The transaction included participation ...
Read More


AZN's price was unchanged after the transaction was announced on 12/19/14.
Investor / Buyer
Alexion Pharmaceuticals, Inc.
AstraZeneca PLC
RA Capital Management, LLC
The Invus Group, LLC
Viking Global Investors L.P.
Wellington Management Company LLP
 
Announced 11/6/14
325.00M for AstraZeneca PLC, Myalept
Merger/Acquisition

Aegerion Pharmaceuticals, Inc. (NasdaqGS:AEGR) entered into a definitive agreement to acquire Myalept from AstraZeneca PLC (LSE:AZN) for approximately $330 million on November 5, 2014. The transaction does not include the transfer of any AstraZeneca employees or facilities. The transaction is subject to closing conditions, including the receipt of Hart-Scott-Rodino antitrust clearance from the US Federal Trade Commission. The companies expect the transaction to complete ...
Read More


AZN's price was unchanged after the transaction was announced on 11/6/14.
Investor / Buyer
Aegerion Pharmaceuticals, Inc.
Creditor / Lender
AstraZeneca PLC
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:US $68.18 USD +0.39

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $56.86 USD -3.41
Biogen Idec Inc $425.61 USD +11.48
Celgene Corp $120.71 USD +1.14
Eli Lilly & Co $70.59 USD -0.06
Novo Nordisk A/S kr318.00 DKK +2.40
View Industry Companies
 

Industry Analysis

AZN

Industry Average

Valuation AZN Industry Range
Price/Earnings 69.2x
Price/Sales 3.3x
Price/Book 4.3x
Price/Cash Flow 69.2x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC-SPONS ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.